Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Eli Lilly · Phase 1 · Completed · Enrollment 50

NCT06186622

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Cohort 1: Oral Drug Dosing With or Without Orforglipron Co-Administrationn/rn/rn/rn/r
Cohort 2: Oral Drug Dosing With or Without Orforglipron Co-Administrationn/rn/rn/rn/r

Not shown

  • Cohort 1: Oral Drug Dosing With or Without Orforglipron Co-Administration: endpoint not reported
  • Cohort 2: Oral Drug Dosing With or Without Orforglipron Co-Administration: endpoint not reported